Prime Peptide Solutions score history

Score over time

Every entry newest first

1. November 2, 2026Lowered from7.15→to7.14(-0.01)

   Market medians updated after Snowman Research was added pricing 7.3 to 7.2.

2. November 1, 2026Raised from7.14→to7.15(+0.01)

   Market medians updated after Bluum Peptides was added pricing 7.2 to 7.3.

3. October 30, 2026Raised from5.54→to7.14(+1.60)

   Re-check on 30 October 2026: on 28 October the vendor posted certificates for the ten products that had none (nine BT Labs reports tested on 26 October 2026 and an ILS certificate for NAD+). The ILS certificate was confirmed at the laboratory's portal; the BT Labs reports sit behind an identity form at the laboratory, so they count as key printed but not confirmed. Every one of the 20 products we list now has a certificate. Lab 4.4 to 7.3.

4. October 29, 2026Raised from5.53→to5.54(+0.01)

   Market medians updated after Delix Labs and Ageless Peptides were added pricing 7.1 to 7.2.

5. October 27, 2026Lowered from5.54→to5.53(-0.01)

   Market medians updated after S1Research was added pricing 7.2 to 7.1.

6. October 27, 2026Raised from5.51→to5.54(+0.03)

   Pricing recomputed on 27 October 2026: listings added for a newly reviewed vendor (Peptide Pro) moved the market median for the same products pricing 7.0 to 7.2.

7. October 27, 2026Lowered from5.54→to5.51(-0.03)

   Pricing recomputed on 27 October 2026: listings added for a newly reviewed vendor (NovaForge Labs) moved the market median for the same products: pricing 7.2 to 7.0.

8. October 26, 2026Lowered from5.57→to5.54(-0.03)

   Pricing recomputed on 26 October 2026: listings added for a newly reviewed vendor (StudzPeptides) moved the market median for the same products: pricing 7.4 to 7.2.

9. October 25, 2026Lowered from5.59→to5.57(-0.02)

   Pricing recomputed on 25 October 2026: listings added for a newly reviewed vendor (Pexo Labs) moved the market median for the same products: pricing 7.5 to 7.4.

10. October 24, 2026Raised from5.57→to5.59(+0.02)

    Prices re-computed on 24 October 2026 after products were added for Spartan Peptides, Next Day Peptides and Honest Peptide, which moved the market medians: pricing 7.4 to 7.5.

11. October 24, 2026Lowered from5.60→to5.57(-0.03)

    Pricing recomputed on 24 October 2026 after Bionova Peptides' first-review prices were recorded; other vendors move only through the market medians: pricing 7.6 to 7.4.

12. October 23, 2026Lowered from5.62→to5.60(-0.02)

    Pricing recomputed on 23 October 2026 under the revised rule E1 (standing offers), which prices a size at the lowest total a buyer can pay without a code under standing prices, so a standing offer that includes a second vial at no extra cost now counts at all the milligrams received, in the vendor's own price and in the market medians for the same products: pricing 7.7 to 7.6.

13. October 23, 2026Raised from5.60→to5.62(+0.02)

    Pricing recomputed on 23 October 2026 from current listings with the published rule (section E), after listings added or updated since 22 October, including a newly reviewed vendor's, moved the market median for the same products: pricing 7.6 to 7.7.

14. October 22, 2026Raised from5.27→to5.60(+0.33)

    Lab score recalculated on 22 October 2026 under the published core-product rule (A1b): a missing certificate on one of the 15 most widely carried products still counts fully, while on any other product it now counts at half weight, so a broad catalogue is not penalised as much for its breadth. Lab 3.8 to 4.4.

15. October 22, 2026Raised from5.22→to5.27(+0.05)

    Claim deductions re-checked on 22 October 2026 under the published rule that a claim deduction applies only where a site claim is contradicted by what its certificates show, never for products merely lacking a certificate. Lab 3.7 to 3.8.

16. October 22, 2026Raised from5.19→to5.22(+0.03)

    Re-scored on 22 October 2026 under the published rulebook, which now gives one rule for each judgement call and applies it to every vendor: transparency 7.0 to 7.5.

17. October 22, 2026Raised from5.17→to5.19(+0.02)

    Re-scored on 22 October 2026 under our published rubric for shipping, pricing, operating history and transparency, applied to every vendor the same day: prices re-read from the vendor's site and matched by milligrams per vial, operating history from the earliest dated evidence of the business, and policies scored item by item. shipping and refunds 7.5 to 8.0, pricing 8.1 to 7.6, operating history 2.0 to 1.3, transparency 6.5 to 7.0.

18. October 22, 2026Lowered from5.50→to5.17(-0.33)

    Lab score recalculated on 22 October 2026 under the uniform published rubric applied to every vendor: ILS Laboratories, which issued certificates relied on here, does not publish ISO/IEC 17025 accreditation, so the accreditation point no longer applies; fixed deductions apply for site statements about testing that the certificates do not bear out and one lot number printed on certificates for different compounds. Lab 4.3 to 3.7. Note added 22 October 2026: PJLA's register lists ILS Laboratories' accreditation (certificate L25-631) as suspended from 22 October 2026; the accreditation point still does not apply (check L6).

19. October 20, 2026Lowered from6.60→to5.50(-1.10)

    Lab evidence re-checked on 20 October 2026 under our coverage rule, which counts a listed product with no published certificate as zero in the lab average. Certificates cover 10 of the 20 products we list that the vendor offers for sale. Lab 6.3 to 4.3.

20. October 18, 2026Raised from6.42→to6.60(+0.18)

    Correction. The initial audit stated that the certificate library listed the wrong purity for the seven older Kovera batches. That was our error: the library and every batch page show Kovera's own figures. Lab rises from 6.0 to 6.3 and transparency from 6.0 to 6.5. Coverage (about ten of twenty-eight compounds) and the absence of endotoxin and sterility testing still limit the lab score.

21. October 18, 2026First publishedat6.42

    lab 6.0 / shipping 7.5 / pricing 8.1 / tenure 2.0 / transparency 6.0.